JP2002534130A5 - - Google Patents

Download PDF

Info

Publication number
JP2002534130A5
JP2002534130A5 JP2000593765A JP2000593765A JP2002534130A5 JP 2002534130 A5 JP2002534130 A5 JP 2002534130A5 JP 2000593765 A JP2000593765 A JP 2000593765A JP 2000593765 A JP2000593765 A JP 2000593765A JP 2002534130 A5 JP2002534130 A5 JP 2002534130A5
Authority
JP
Japan
Prior art keywords
fiber
adenovirus
tpl
cells
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000593765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534130A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2000/000265 external-priority patent/WO2000042208A1/en
Publication of JP2002534130A publication Critical patent/JP2002534130A/ja
Publication of JP2002534130A5 publication Critical patent/JP2002534130A5/ja
Pending legal-status Critical Current

Links

JP2000593765A 1999-01-14 2000-01-14 アデノウイルスベクター、パッケージ細胞系、組成物および製法および使用法 Pending JP2002534130A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11592099P 1999-01-14 1999-01-14
US60/115,920 1999-01-14
PCT/EP2000/000265 WO2000042208A1 (en) 1999-01-14 2000-01-14 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use

Publications (2)

Publication Number Publication Date
JP2002534130A JP2002534130A (ja) 2002-10-15
JP2002534130A5 true JP2002534130A5 (cg-RX-API-DMAC10.html) 2007-05-31

Family

ID=22364147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000593765A Pending JP2002534130A (ja) 1999-01-14 2000-01-14 アデノウイルスベクター、パッケージ細胞系、組成物および製法および使用法

Country Status (7)

Country Link
EP (1) EP1141357A1 (cg-RX-API-DMAC10.html)
JP (1) JP2002534130A (cg-RX-API-DMAC10.html)
KR (1) KR100688631B1 (cg-RX-API-DMAC10.html)
AU (2) AU772630B2 (cg-RX-API-DMAC10.html)
CA (1) CA2359795A1 (cg-RX-API-DMAC10.html)
IL (1) IL144060A0 (cg-RX-API-DMAC10.html)
WO (1) WO2000042208A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
CN1405312A (zh) * 2001-01-18 2003-03-26 中山卫健生物科技有限公司 一种能特异性杀灭eb病毒相关肿瘤的重组病毒及其构建方法
EP1470250A2 (en) * 2001-07-15 2004-10-27 Keck Graduate Institute Gene expression analysis using nicking agents
AU2007231692B8 (en) * 2001-10-11 2012-03-08 Msd Italia S.R.L. Hepatitis C virus vaccine
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション C型肝炎ウイルスワクチン
US8163892B2 (en) 2002-07-08 2012-04-24 Oncolys Biopharma, Inc. Oncolytic virus replicating selectively in tumor cells
CA2519680A1 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
ES2330826B1 (es) * 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
US8722853B2 (en) * 2010-06-10 2014-05-13 University Of Washington Through Its Center For Commercialization Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN110832072B (zh) * 2017-04-21 2023-11-07 真基因太科公司 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3864159A4 (en) * 2018-10-09 2022-11-02 Nikegen Limited Compositions and methods for preparing viral vectors
WO2021072112A1 (en) 2019-10-09 2021-04-15 Hdt Bio Corp. Detection of desmoglein-2 in cancers of epithelial origin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705344B8 (en) * 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
EP0929644B1 (de) * 1996-09-24 2001-11-21 HENKEL-ECOLAB GmbH & CO. OHG Herstellung tensidhaltiger kompaktreiniger
EP1471146B1 (en) * 1996-09-25 2009-01-07 Novartis AG A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
EP0892047A3 (de) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L

Similar Documents

Publication Publication Date Title
Zhou et al. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted
US6228646B1 (en) Helper-free, totally defective adenovirus for gene therapy
JP3532566B2 (ja) 遺伝子治療のためのアデノウイルスベクター
US11795477B2 (en) Single cycle replicating adenovirus vectors
US6156497A (en) Recombinase-mediated generation of adenoviral vectors
JP3565859B2 (ja) 改良されたアデノウイルスおよびその使用法
US6365394B1 (en) Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
Michou et al. Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors
JP4733795B2 (ja) ヒツジアデノウイルスベクターを用いた遺伝子治療
US20090098599A1 (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP1135515A2 (en) Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene
US5985846A (en) Gene therapy for muscular dystrophy
Loser et al. Advances in the development of non-human viral DNA-vectors for gene delivery
EP1141357A1 (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
JP2003534805A (ja) 変化した親和性を有する改変ウシアデノウイルス
WO2002008436A2 (en) Mini-adenoviral vector system for vaccination
AU2003242160B2 (en) Adenovirus vector
US20020168341A1 (en) Enhanced system for construction of adenovirus vectors
US7585498B2 (en) Regulation of adenovirus DNA packaging by IPTG
LE et al. FLUORESCENT LABELING OF CANINE ADENOVIRUS TYPE 2 WITH pIX-EGFP
EP1104813A1 (en) Conditional replication of recombinant human adenovirus DNA carrying modified inverted terminal repeat sequences
JPH104973A (ja) 組換えバキュロウイルス及びその利用
MXPA01003840A (en) Selectively replicating viral vectors
MXPA01004989A (en) Viral vectors with late transgene expression